NASDAQ$PCVX
Vaxcyte Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Vaxcyte reported fourth quarter and full year 2023 financial results and provided a business update.
Vaxcyte reported a net loss of $180.8 million for the fourth quarter of 2023. The company's cash, cash equivalents and investments were $1,242.9 million as of December 31, 2023, excluding net proceeds of $816.5 million from a recent public offering. The company also completed enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of IPD in Adults Aged 50 and Older.
- Completed Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of IPD in Adults Aged 50 and Older; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024
- Completed Successful VAX-24 Phase 2 Adult Program and End-of-Phase 2 Meeting; VAX-24 is Phase 3-Ready in Adults
- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program
- Completed Two Successful Follow-On Financings Totaling Approximately $1.4 Billion in Gross Proceeds, Further Strengthening Vaxcyte’s Balance Sheet
Headline financials
Revenue & EPS history
Vaxcyte · Revenue · Quarterly
$14.4M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+0.6%
Avg return
Earnings day
+0.8%
Avg return
5 days after
-0.2%
Avg return
30 days after
50%
11 / 22 earnings
Positive
+23.8%
Q2 2020
Best reaction
-21.5%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +2.7% | +1.0% | -13.3% | |
| Q3 2025 | -2.5% | +3.8% | +12.4% | |
| Q2 2025 | -9.1% | -9.1% | +0.1% | |
| Q1 2025 | +8.3% | +3.6% | +27.6% | |
| Q4 2024 | -0.9% | -9.1% | -12.5% | |
| Q3 2024 | -2.3% | +0.2% | -15.4% | |
| Q1 2024 | -2.9% | -2.7% | +5.1% | |
| Q4 2023 | -4.9% | -9.2% | -13.5% | |
| Q3 2023 | -1.0% | -5.1% | +10.8% | |
| Q2 2023 | -2.5% | -2.0% | +3.4% | |
| Q1 2023 | +3.7% | -3.7% | -0.3% | |
| Q4 2022 | -1.8% | +2.0% | -11.6% | |
| Q3 2022 | +4.2% | +3.3% | +0.6% | |
| Q2 2022 | +0.4% | +1.7% | +6.1% | |
| Q1 2022 | -11.4% | -3.0% | -14.8% | |
| Q4 2021 | +5.5% | +1.5% | +6.5% | |
| Q3 2021 | +3.4% | +4.7% | -12.7% | |
| Q2 2021 | +5.1% | +3.6% | +3.1% | |
| Q1 2021 | +13.5% | +17.0% | +40.5% | |
| Q4 2020 | -21.5% | -11.9% | -17.3% | |
| Q3 2020 | +3.9% | -0.2% | -15.3% | |
| Q2 2020 | +23.8% | +31.0% | +5.5% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro